Filing Flows

Filing Flows › Companies › Balchem › Cash flow

Balchem cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$69.8M in Q3 2026 · $224M over twelve months

Operating cash flow$69.8M
Free cash flow+$69.8M
Cash / net income1.5×
Cash conversion cycle95 days

Analysis

In Q3 2026, Balchem generated $69.8M of operating cash flow. That is $4.2M more than in Q3 2025 ($65.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was $224M; the largest uses were buybacks ($126M), other investing ($46.2M), dividends ($30.8M); besides operations, cash came from shares issued ($14.0M), asset & business sales ($14K); the cash balance rose by $1.2M.

Operating cash flow was $69.8M against net income of $46.7M — 1.5× profit, cash ran ahead of reported earnings. The largest differences: inventory −$15.9M, payables +$14.7M, depreciation & amortization +$12.4M.

Its cash conversion cycle was 95 days (receivables 47 + inventory 84 − payables 35).

Free cash flow

Balchem: free cash flow by quarterBalchem: free cash flow by quarter$52.3MQ4 2024$36.5MQ1 2025$47.3MQ2 2025$65.6MQ3 2025$67.3MQ4 2025$40.1MQ1 2026$46.7MQ2 2026$69.8MQ3 2026
Operating cash flow less capital spending.
Balchem: operating cash flow against capital spendingBalchem: operating cash flow against capital spendingOperating cash flowCapital spending$52.3M$0Q4 2024$36.5M$0Q1 2025$47.3M$0Q2 2025$65.6M$0Q3 2025$67.3M$0Q4 2025$40.1M$0Q1 2026$46.7M$0Q2 2026$69.8M$0Q3 2026
Latest (Q3 2026): Operating cash flow $69.8M, Capital spending $0.

Capital allocation, year by year

Balchem: where the cash came from (up) and went (down), by fiscal yearBalchem: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksDividendsFY2021: Operating cash flow $161MFY2021: Net borrowing −$55.2MFY2021: Shares issued $6.9MFY2021: Asset sales $318KFY2021: Capital spending −$36.1MFY2021: Buybacks −$35.2MFY2021: Dividends −$18.7M$168MFY2021FY2022: Operating cash flow $139MFY2022: Net borrowing $332MFY2022: Shares issued $3.2MFY2022: Asset sales $206KFY2022: Capital spending −$49.1MFY2022: Acquisitions −$366MFY2022: Buybacks −$35.4MFY2022: Dividends −$20.7M$474MFY2022FY2023: Operating cash flow $184MFY2023: Net borrowing −$131MFY2023: Shares issued $5.2MFY2023: Asset sales $1.9MFY2023: Acquisitions −$1.3MFY2023: Buybacks −$4.5MFY2023: Dividends −$22.9M$191MFY2023FY2024: Operating cash flow $182MFY2024: Net borrowing −$120MFY2024: Shares issued $17.2MFY2024: Asset sales $359KFY2024: Acquisitions −$24.2MFY2024: Buybacks −$5.7MFY2024: Dividends −$25.6M$200MFY2024FY2025: Operating cash flow $217MFY2025: Net borrowing −$26.2MFY2025: Shares issued $9.3MFY2025: Asset sales $274KFY2025: Acquisitions −$323KFY2025: Buybacks −$108MFY2025: Dividends −$28.3M$226MFY2025
Over these 5 years operating cash flow totalled $881M; the largest uses were acquisitions ($392M) and net borrowing ($332M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$66.3M
Debtnone
Net cash$66.3M

Balchem funds itself: free cash flow was $224M over the last twelve months, with $66.3M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Balchem: sources (+) and uses (−) of cash, Q3 2026Balchem: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$69.8MNet borrowing (+) / repaid (−)−$28.1MBuybacks−$27.4MOther investing−$12.5MShares issued$3.8MCash drawn (+) / kept (−)−$3.1MOther financing−$1.9MExchange rates−$566KDividends−$1K
Balchem: sources (+) and uses (−) of cash, TTM to Q3 2026Balchem: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$224MBuybacks−$126MOther investing−$46.2MDividends−$30.8MNet borrowing (+) / repaid (−)−$30.2MShares issued$14.0MExchange rates−$2.0MOther financing−$1.9MCash drawn (+) / kept (−)−$1.2MAsset & business sales$14K

From profit to cash

Balchem: net income to operating cash flow, Q3 2026Balchem: net income to operating cash flow, Q3 2026Net income$46.7MDepreciation & amortization$12.4MStock-based pay$5.0MDeferred taxes−$506KReceivables$3.5MInventory−$15.9MPayables$14.7MPrepaid and other assets−$2.1MIncome taxes payable$3.2MOperating cash flow$69.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202647843595
Q2 202649783691
Q1 202650743589
Q4 202548722990
Q3 202546753190
Q2 202547823892
Q1 202545763388
Q4 202446753090

Every quarter

QuarterOperating cash flowAcquisitionsBuybacksDividendsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$69.8M—−$27.4M−$1K−$28.1M$3.8M−$3.1M$69.8M
Q2 2026$46.7M—−$28.8M−$3K−$17.1M$1.0M$9.7M$46.7M
Q1 2026$40.1M—−$15.7M−$30.8M$4.9M$6.7M$1.7M$40.1M
Q4 2025$67.3M—−$53.6M−$11K$10.0M$2.4M−$9.5M$67.3M
Q3 2025$65.6M—−$15.4M−$11K−$36.0M$645K$334K$65.6M
Q2 2025$47.3M—−$33.3M−$2K−$48K$4.6M−$15.5M$47.3M
Q1 2025$36.5M−$323K−$5.3M−$28.3M−$49K$1.7M−$386K$36.5M
Q4 2024$52.3M−$24.2M−$306K−$4K−$37.0M$2.1M$24.2M$52.3M

Balchem: income statement and cash flow

Balchem, Q3 2026: revenue $291M (+9% year over year), operating margin 21.5%. The chart follows the revenue to costs, profit and cash.

Balchem: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.